Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

2.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

6.1K
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
6.1K
Experimental RNAi02:15

Experimental RNAi

6.5K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.5K
MicroRNAs01:22

MicroRNAs

3.3K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Traditional Chinese medicine in the treatment of breast Cancer.

Molecular cancer·2025
Same author

Interaction of glaucocalyxin a with glutathione and thioredoxin reductase for triple-negative breast cancer treatment.

Bioorganic chemistry·2025
Same author

Imaging of sulfhydryl fluctuations in mouse models of drug-induced liver injury via a novel near-infrared fluorescence probe.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2025
Same author

Targeting thioredoxin reductase by eupalinilide B promotes apoptosis of colorectal cancer cells in vitro and in vivo.

Chemico-biological interactions·2024
Same author

Corrigendum to "Inhibition of thioredoxin reductase by alantolactone prompts oxidative stress-mediated apoptosis of HeLa cells" [Biochem. Pharmacol. 102 (2016) 34-44].

Biochemical pharmacology·2024
Same author

Fluorescent Probes for Mammalian Thioredoxin Reductase: Mechanistic Analysis, Construction Strategies, and Future Perspectives.

Biosensors·2023
Same journal

Advancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies.

Frontiers in cell and developmental biology·2026
Same journal

CRISPR-based next-generation molecular diagnostics for bone infection.

Frontiers in cell and developmental biology·2026
Same journal

Tissue turnover and rejuvenation through mechanics.

Frontiers in cell and developmental biology·2026
Same journal

Decoding signaling crosstalk in pulpitis: pathogenesis and precision therapeutics.

Frontiers in cell and developmental biology·2026
Same journal

Embryonic scaling: morphogen gradients, size sensing, and scaler genes.

Frontiers in cell and developmental biology·2026
Same journal

H<sub>2</sub>S-mediated protein S-sulfhydration: a novel regulatory module in lipid metabolism.

Frontiers in cell and developmental biology·2026
See all related articles

Related Experiment Video

Updated: Oct 17, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

750

Non-coding RNAs in Regulating Tumor Angiogenesis.

Xin Song1, Yanan Guo2, Peng Song3,4

  • 1School of Life Sciences and Engineering, Lanzhou University of Technology, Lanzhou, China.

Frontiers in Cell and Developmental Biology
|October 7, 2021
PubMed
Summary
This summary is machine-generated.

Non-coding RNAs (ncRNAs) regulate tumor blood vessel growth (angiogenesis). Dysregulated ncRNAs can act as oncogenes or tumor suppressors, impacting cancer development and offering therapeutic targets.

Keywords:
biological functionmolecular mechanismncRNAtumor angiogenesistumor metabolism

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Related Experiment Videos

Last Updated: Oct 17, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
07:23

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

750
Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

6.1K

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Non-coding RNAs (ncRNAs) are crucial regulators in physiological and pathological processes, including cancer.
  • Tumor angiogenesis, the formation of new blood vessels in tumors, is vital for cancer growth and metastasis.
  • ncRNAs play significant roles in modulating the complex processes of tumor angiogenesis.

Purpose of the Study:

  • To review the diverse biological functions of ncRNAs.
  • To elucidate the regulatory mechanisms by which ncRNAs impact tumor angiogenesis.
  • To highlight the potential of ncRNAs as therapeutic targets in cancer management.

Main Methods:

  • Literature review of existing research on ncRNAs and tumor angiogenesis.
  • Analysis of studies detailing the functions and regulatory pathways of ncRNAs.
  • Synthesis of information on abnormal ncRNA expression in cancer.

Main Results:

  • ncRNAs are key players in controlling angiogenesis, acting as either tumor suppressors or oncogenes.
  • Abnormal expression of specific ncRNAs directly influences tumor development and progression.
  • Understanding these regulatory roles provides insights into cancer biology.

Conclusions:

  • ncRNAs are critical regulators of tumor angiogenesis with significant implications for cancer.
  • Targeting ncRNAs offers a promising avenue for novel cancer therapies.
  • Further research into ncRNA mechanisms will advance cancer treatment strategies.